A substantial majority (70.7%–94.8%) felt that results regarding pathogenic or likely pathogenic variants in a gene known to cause PD or other neurodegenerative diseases, as well as variants known to increase the risk of PD (e.g., GBA1 variants) should be returned. Here, GBA1 is linked to Parkinson disease.